보고서 요약(국문)

개요
전 세계 부신 기능 부전 시장은 2022년 3억 6,770만 달러에 달했으며, 2023년부터 2030년까지 연평균 10.5%의 성장률을 보이며 2030년에는 8억 190만 달러에 이를 것으로 예상됩니다.
부신 기능 부전은 원발성, 이차성, 삼차성의 세 가지 유형으로 나뉩니다. 원발성 부신 기능 부전은 흔히 애디슨병으로 불리며, 신체에서 특정 호르몬을 충분히 생산하지 못할 때 발생하는 드문 질환입니다. 애디슨병에서는 부신에서 코르티솔이 매우 적게 생산되고, 종종 또 다른 호르몬인 알도스테론은 과다하게 생산됩니다. 부신 기능 부전의 유형별 원인은 다양합니다. 부신 기능 부전의 가장 흔한 원인은 장기간 코르티코스테로이드를 복용한 후 갑자기 중단하는 것입니다.

부신 기능 부전은 신체의 스트레스 반응 능력과 기타 기본적인 생명 유지 기능에 영향을 미칠 수 있습니다. 치료를 받으면 대부분의 부신 기능 부전 환자는 정상적이고 활동적인 삶을 영위할 수 있습니다. 애디슨병은 선진국에서는 드물며, 인구 백만 명당 약 100~140명에게 영향을 미칩니다. 그러나 이차성 부신 기능 부전은 매우 흔하며, 백만 명당 150~280명에게 영향을 미칩니다. 이차성 및 삼차성 부신 기능 부전은 일반적으로 함께 분류되므로 삼차성 부신 기능 부전에 대한 별도의 통계는 없습니다.
다양한 치료법에 대한 연구 활동 증가와 여러 규제 기관의 승인은 예측 기간 동안 전 세계 부신 기능 부전 시장 성장을 촉진하는 주요 요인 중 하나입니다. 또한, 인식 개선 활동과 다양한 단체의 지원 효과도 예측 기간 동안 전 세계 부신 기능 부전 시장 성장에 기여하고 있습니다.

시장 동향
연구 활동 및 제품 승인 증가
연구 활동 및 제품 승인 증가는 예측 기간 동안 전 세계 부신 기능 부전 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2022년 1월 미국 식품의약국(FDA)은 성인 및 청소년의 급성 부신 기능 부전 치료제인 ATRS-1902에 대해 신속 심사(Fast Track) 지정을 승인했습니다. 이 지정은 부신 위기에 대한 ATRS-1902의 1상 임상 연구에서 긍정적인 결과가 나온 것을 바탕으로 이루어졌습니다.
또한, 2022년 2월 Diurnal은 서방형 하이드로코르티손의 유럽 2상 임상 연구에서 첫 번째 환자에게 투여가 완료되었다고 발표했습니다. 애디슨병으로도 알려진 부신 기능 부전(AI) 환자 치료에 사용되는 이 임상 시험은 유럽 및 영국 전역에서 회사에 상당한 사업 기회를 제공할 것으로 기대됩니다. CHAMPAIN 2상 임상시험은 부신 기능 부전 환자에서 서방형 히드로코르티손과 플레나드렌의 효과, 안전성 및 내약성을 비교 평가하는 것을 목표로 합니다.
부신 기능 부전 환자 수 증가
부신 기능 부전 환자 수의 증가는 향후 예측 기간 동안 세계 시장 성장에 기여할 것으로 예상됩니다. 예를 들어, 여러 연구에 따르면 정상 체액량 저나트륨혈증으로 응급실을 방문하는 환자 중 2.7~3.8%에서 진단되지 않은 부신 기능 부전이 발견되었으며, 전문 치료 병동에 입원한 환자에서는 이 비율이 최대 15%까지 증가합니다. 또한, 미국 국립보건원(NIH)에 따르면 선진국에서 약 1억 4,400만 명이 애디슨병을 앓고 있습니다.

또한, 2023년에 발표된 "부신 기능 부전의 진단 및 관리"라는 제목의 논문에 따르면, 원발성 부신 기능 부전의 유병률은 백만 명당 93~140명으로 추산됩니다. 서구권에서는 자가면역성 부신염이 원발성 부신 기능 부전 환자의 70% 이상을 차지합니다. 이차성 부신 기능 부전은 원발성보다 흔하며, 유병률은 백만 명당 150~280명입니다. 이차성 부신 기능 부전의 가장 흔한 원인은 외인성 글루코코르티코이드 사용으로, 염증성 또는 면역 매개 질환으로 인해 이 약물을 복용하는 사람의 최대 2.5%가 이차성 부신 기능 부전을 겪고 있으며, 약물 투여를 갑자기 중단할 경우 스테로이드 결핍에 취약해집니다.
엄격한 절차와 높은 신약 개발 비용
낮은 성공 확률과 함께 길고 엄격한 신약 개발 및 상용화 절차는 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다. 예를 들어, 임상 연구의 가장 분명한 목적은 식품의약품안전청(FDA) 승인을 얻기 위해 안전성과 유효성을 입증하는 것입니다. FDA는 허용 가능한 임상 투자와 공정한 결과에 대한 권고 사항을 개발자에게 제공합니다. 특히 충분하고(즉, 안전성 또는 유효성에 대한 추가 데이터를 더 많이 제공하고) 신속한 임상 연구를 수행함으로써 신약 개발 접근 방식을 개선하면 의료 제품 개발의 혁신을 촉진할 수 있습니다.
새로운 의약품을 상용화하기 위해 FDA 승인을 받으려는 제약 회사는 발견/개념, 전임상 연구, 임상 연구, FDA 검토 및 FDA 시판 후 안전성 모니터링의 5단계 과정을 거쳐야 하므로 의약품 개발 및 상용화가 어렵습니다. 또한 신약 개발에 드는 막대한 비용은 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다. 예를 들어, 자금 지출과 시장 승인을 받지 못한 의약품에 대한 비용을 포함한 신약 개발 예상 비용은 10억 달러 미만에서 20억 달러 이상까지 다양하게 추산됩니다.

인식 부족
부신 기능 부전은 유병률이 낮아 이에 대한 인식이 부족하며, 이는 향후 전 세계 부신 기능 부전 시장 성장을 둔화시킬 것으로 예상됩니다. 예를 들어, 미국 국립보건원(NIH)에 따르면 애디슨병은 드문 질환입니다. 연간 유병률은 인구 10만 명당 0.6명입니다. 특정 시점에 이 질환의 영향을 받는 사람의 수는 인구 10만 명당 4명에서 11명 사이입니다.
또한, 부신 기능 부전은 초기 단계에서 증상이 서서히 나타나기 때문에 진단이 어렵다는 점도 인식 부족의 원인 중 하나입니다. 의료 전문가는 환자의 병력과 증상을 검토한 후 추정할 수 있으며, 이후 혈액 검사를 통해 코르티솔 수치가 너무 낮은지 확인하고 원인을 파악합니다.

세그먼트 분석
전 세계 부신 기능 부전 시장은 유형, 원인, 치료법, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
선천성 부신 기능 부전 유형이 시장을 주도할 것으로 예상됩니다.
선천성 부신 과형성증(CAH)은 스테로이드 생성 장애로 인해 코르티솔 및/또는 알도스테론이 다양하게 부족해지고, 이로 인해 신진대사와 전해질에 생명을 위협하는 등 악영향을 미치는 질환들을 총칭하는 용어입니다. 또한, 안드로겐이 과다 생성되어 남성화 효과를 나타냅니다. 연구 활동의 증가로 인해 예측 기간 동안 해당 세그먼트의 성장이 촉진될 것으로 예상됩니다.
예를 들어, 2023년 2월, 생명공학 기업 HBM Alpha Therapeutics는 선천성 부신 과형성증(CAH) 및 다낭성 난소 증후군(PCOS) 치료를 위한 새로운 항체 치료제 개발을 위해 시드 투자를 유치했으며, 현재 가장 유력한 후보 물질이 임상시험계획승인신청(IND) 단계에 있습니다. 또한, 임상시험정보관리기관(clinical trials.gov)에 따르면 현재 선천성 부신 증식증 치료를 위한 다양한 치료법을 연구하는 5건의 중재 연구(4상 1건, 1상 1건, 3상 3건)가 활발히 진행 중입니다.
지리적 시장 침투
북미 지역의 안과 질환 환자 수 증가
부신 기능 부전증 환자 수 증가와 이 지역의 시장 개발 성장은 예측 기간 동안 북미 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 희귀 질환 단체에 따르면 애디슨병은 남녀에게 비슷한 유병률로 발생합니다. 미국에서는 약 10만 명당 1명꼴로 애디슨병을 앓고 있습니다. 전체 인구의 백만 명당 유병률은 40~60명으로 추산됩니다.
또한, 이 지역의 시장 개발은 지역 시장 성장에 기여하고 있습니다. 예를 들어, 2021년 6월, 소아 부신피질기능부전 치료제인 알킨디 스프링클(ALKINDI SPRINKLE)의 미국 판매사인 이튼 파마슈티컬스(Eton Pharmaceuticals, Inc.)는 부신 위기 회복 치료제로 개발 중인 크로스젝트(Crossject)의 제네오(ZENEO) 하이드로코르티손 무바늘 자동주사기의 미국 및 캐나다 지분을 인수했습니다.
코로나19 영향 분석
코로나19 팬데믹은 전 세계 의료 시스템에 혼란을 야기했으며, 희귀 질환의 진단, 치료 및 연구 활동에 차질을 초래하여 부신기능부전을 포함한 전체 희귀 질환 시장 성장에 부정적인 영향을 미쳤습니다. 그러나 부신기능부전은 코로나19 후유증 중 하나로 여겨져 진단 및 치료 수요가 증가하면서 시장 성장에 긍정적인 영향을 미쳤습니다.
예를 들어, 미국 국립보건원(NIH)에 따르면 코로나19는 내분비계를 비롯한 여러 장기와 시스템에 영향을 미칠 수 있습니다. 그 증상은 수개월 동안 지속될 수 있으며, 그 결과 코로나19 후유증 등이 발생할 수 있습니다. 소수의 사례에서 코로나19 완치 후 수개월이 지나 중추성 부신 기능 부전(CAI)이 보고되었지만, 그 병태생리는 아직 완전히 밝혀지지 않았습니다.
유형별
• 원발성
• 이차성
• 삼차성
원인별
• 선천성
• 후천성
치료법별
• 글루코코르티코이드
• 코르티코트로핀
• 기타
투여 경로별
• 경구
• 주사제
• 기타
유통 채널별
• 병원 약국
• 일반 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2022년 4월, 디우르날 그룹은 얼킴과의 유통 계약을 확대하여 알킨디(개봉용 캡슐에 담긴 히드로코르티손 과립)와 에프모디의 유통 및 마케팅을 담당하게 되었습니다. (히드로코르티손 서방형 경질 캡슐)은 그리스, 키프로스, 몰타에서 판매되고 있습니다.

• 2021년 6월, 이튼 파마슈티컬스(Eton Pharmaceuticals)는 부신 기능 부전 회복 치료제로 개발 중인 크로스젝트(Crossject)의 제네오(Zeneo) 히드로코르티손 무바늘 자동주사기의 미국 및 캐나다 판매권을 인수했습니다.

경쟁 환경
주요 글로벌 시장 참여 기업으로는 아크로텍 바이오파마(Acrotech Biopharma, Inc.), 바우쉬 헬스 캐나다(Bausch Health, Canada Inc.), 애드바케어 파마(AdvaCare Pharma), 위프셀파마(Weefselpharma), 시플라(Cipla Inc.), 화이자(Pfizer Inc.), 웰로나 파마(Wellona Pharma), 유지아 US(Eugia US), 산도즈(Sandoz Inc.), 프레베고 헬스케어 & 리서치(Prevego Healthcare & Research Pvt Ltd.) 등이 있습니다.

보고서 구매 이유

• 유형, 원인, 치료법, 투여 경로, 유통 채널 및 지역별 글로벌 부신 기능 부전 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위함입니다.

• 모든 세그먼트를 포함한 부신 기능 부전 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 부신 기능 부전 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Adrenal Insufficiency Market reached US$ 367.7 million in 2022 and is expected to reach US$ 801.9 million by 2030, growing with a CAGR of 10.5% during the forecast period 2023-2030.
Adrenal insufficiency is of three types namely the primary, secondary, and tertiary. Primary adrenal insufficiency is often anointed as Addison's disease is an uncommon condition that transpires when the body doesn't produce sufficient amounts of specific hormones. In Addison's disorder, the adrenal glands produce very small quantities of cortisol and, frequently, excessively small quantities of another hormone, aldosterone. Distinct kinds of adrenal insufficiency hold diverse reasons. The highly expected reason for adrenal insufficiency overall is abruptly ceasing corticosteroids after taking them for a prolonged period.
Adrenal insufficiency can impact the body’s capability to react to stress and support other fundamental life processes. With treatment, the majority of individuals with adrenal insufficiency can live a normal, active life. Addison’s disease is rare in developed nations, it impacts approximately 100 to 140 per million individuals. However, secondary adrenal insufficiency is highly typical, impacting 150 to 280 individuals per million. Secondary and tertiary adrenal insufficiency are usually grouped jointly, so no statistics for tertiary adrenal insufficiency separately are available.
The increasing research activities and authorizations from distinct regulatory bodies for different treatments are among the primary factors boosting the global adrenal insufficiency market growth during the forecast period. Further, the growing awareness initiatives and support effects from diverse groups are also contributing to the global adrenal insufficiency market growth in the forecast period.
Dynamics
Increasing Research Activities and Product Authorizations
The increasing research activities and product authorizations are expected to boost the global adrenal insufficiency market growth during the forecast period. For instance, in January 2022, the Food and Drug Administration (FDA) awarded Fast Track designation to ATRS-1902 to treat acute adrenal insufficiency in adults and adolescents. The designation is awarded on the basis of favorable outcomes from a Phase I clinical investigation for ATRS-1902 for adrenal crisis.
Moreover, in February 2022, Diurnal reported that the foremost patient has been administered in its phase 2 European clinical investigation of modified-release hydrocortisone. Indicated for the treatment of individuals with adrenal insufficiency (AI), also comprehended as Addison’s disorder, the trial even symbolizes a substantial trade possibility for the corporation across Europe and throughout the UK. The CHAMPAIN phase 2 investigation seeks to assess the effectiveness, safety, and tolerability of modified-release hydrocortisone versus Plenadren in adrenal insufficiency.
Growing Prevalence of Adrenal Insufficiency Cases
The growing prevalence of adrenal insufficiency cases is also expected to contribute to the global market growth in the forecast period. For instance, distinct studies have demonstrated that 2.7%-3.8% of emergency room visits of patients with euvolemic hyponatremia hold an undetected underlying adrenal insufficiency, and it increases up to 15% among those admitted to specialized care units. Moreover, according to NIH, around 144 million people in the developed world suffer from Addison's disease.
Further, according to an article titled "Diagnosis and management of adrenal insufficiency" published in 2023, the preponderance of primary adrenal insufficiency is assessed to be 93–140 per million. In the Western globe, autoimmune adrenalitis makes up over 70% of all patients with primary adrenal insufficiency. Secondary adrenal insufficiency is more typical compared to primary, with a preponderance rate of 150–280 per million. It has indicated that exogenous glucocorticoid usage is the most typical reason for secondary adrenal insufficiency having up to 2.5% of the people dosing them for inflammatory or immune-mediated disorders, making them vulnerable to steroid deficiency if the medicine is ceased abruptly.
Stringent Process and High Cost of Drug Development
The long and stringent procedure for drug development and commercialization with low success probability is expected to hamper the global market growth during the forecast period. For instance, the most evident purpose of clinical investigation is to establish safeness and effectiveness to achieve Food and Drug Administration (FDA) clearance. FDA delivers recommendations to designers regarding what constitutes permitted clinical investments and fair results. Enhancing the drug development approach, particularly by conducting sufficient (meaning delivering more additional data on safeness or effectiveness) and more quick clinical investigations, can encourage innovation in medical product development.
A pharmaceutical corporation pursuing FDA authorization to commercialize a new pharmaceutical drug is required to meet a five-step process: discovery/concept, preclinical research, clinical research, FDA review, and FDA post-market safety monitoring, making it difficult to develop and commercialize the drug product. Further, the large expenditure for new drug development is also expected to hamper the global market growth in the forecast period. For instance, the anticipated cost to develop a new drug including funds expenses and expenses on drugs that fail to achieve market approval has been assessed to vary from less than $1 billion to over $2 billion.
Lack of Awareness
Owing to its low prevalence the lack of awareness about adrenal insufficiency condition is expected to slow the global adrenal insufficiency market growth during the forecast. For instance, according to the NIH, Addison's disease is infrequent. The preponderance is 0.6 per 100,000 of the population annually. The whole number of individuals impacted by this disorder at a given time varies from 4 to 11 per 100,000 of the population.
Further, the difficulty in detection is also pushing the gap in the awareness of adrenal insufficiency disorders as in its earlier phases, adrenal insufficiency is difficult to interpret since symptoms manifest gradually. The health care expert may presume post-examining the medical record and signs. The subsequent measure is blood testing to notice if the cortisol levels are too low and to help find the cause.
Segment Analysis
The global adrenal insufficiency market is segmented based on type, source, treatment, route of administration, distribution channel and region.
Congenital Adrenal Insufficiency Type is Expected to Dominate Market
Congenital Adrenal Hyperplasia (CAH) is a term used to represent a bunch of genetically specified conditions of impaired steroidogenesis that result in varying lack of the end outcomes cortisol and/or aldosterone and their deleterious, including life-threatening, impacts on metabolism and electrolytes with concurrent diversion to the pile of androgens and their virilizing outcomes. The increasing research activities are expected to boost segment growth during the forecast period.
For instance, in February 2023, Biotech corporation HBM Alpha Therapeutics secured a seed round to extend its novel antibody therapies for the treatment of congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), with the top nominee presently in the IND-enabling phase. Further, according to the clinical trials.gov presently five interventional studies with one phase 4, one phase 1, and the remaining three phases 3 are active investigation distinct therapeutic for the treatment of congenital adrenal hyperplasia.
Geographical Penetration
Increasing Number of Ophthalmic Disorders Cases in North America
The growing cases of adrenal insufficiency and increasing market developments in this region are estimated to boost the North America market growth in the forecast period. For instance, according to the rare disease organization, Addison's disorder impacts males and females in equal prevalence. Roughly 1 in 100,000 individuals in the United States suffer from Addison's disorder. The general preponderance is assessed to be between 40 and 60 individuals per million of the general population.
Further, the market developments in this region also contribute to the regional market growth. For instance, in June 2021, Eton Pharmaceuticals, Inc, the U.S. marketer of ALKINDI SPRINKLE, a therapy for adrenocortical insufficiency in pediatric individuals, completed the acquisition of U.S. and Canadian ownership to Crossject’s ZENEO hydrocortisone needleless autoinjector, which is under development as a recovery therapy for adrenal crisis.
COVID-19 Impact Analysis
The pandemic disturbed the global healthcare system with disturbances in diagnosis, treatments, and research activities for rare conditions which negatively impacted the overall rare conditions market growth including adrenal insufficiency. However, as adrenal insufficiency was believed to be among the post-COVID-19 complications leading increase in diagnosis and treatment demands having a positive impact on the market growth.
For instance, according to the NIH, coronavirus disease 2019 (COVID-19) can impact numerous organs and systems, such as the endocrine system. Its manifestations can stay for months, resulting in post-COVID-19 disorders, among others. A small number of cases were reported to have central adrenal insufficiency (CAI) months post-recovery from COVID-19; however, its pathogenesis has not been completely explained.
By Type
• Primary
• Secondary
• Tertiary
By Source
• Congenital
• Acquired
By Treatment
• Glucocorticoid
• Corticotropin
• Others
By Route of Administration
• Oral
• Injectables
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In April 2022, Diurnal Group expanded its distribution arrangement with Er-Kim to possess the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsule) in Greece, Cyprus, and Malta.
• In June 2021, Eton Pharmaceuticals completed the acquisition of US and Canadian privileges to Crossject’s Zeneo hydrocortisone needleless autoinjector, which is under development as a recovery therapy for the adrenal crisis.
Competitive Landscape
The major global players in the market include Acrotech Biopharma, Inc., Bausch Health, Canada Inc., AdvaCare Pharma, weefselpharma, Cipla Inc., Pfizer Inc, Wellona Pharma, Eugia US, Sandoz Inc., and Prevego Healthcare & Research Pvt Ltd. among others.
Why Purchase the Report?
• To visualize the global adrenal insufficiency market segmentation based on type, source, treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of adrenal insufficiency market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key product of all the major players.
The global adrenal insufficiency market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Source
3.3. Snippet by Treatment
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research Activities and Product Authorizations
4.1.1.2. Growing Prevalence of Adrenal Insufficiency Cases
4.1.2. Restraints
4.1.2.1. Stringent Process and High Cost of Drug Development
4.1.2.2. Lack of Awareness
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. Distribution Channel Trend
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Primary*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Secondary
7.2.4. Tertiary
8. By Source
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
8.1.2. Market Attractiveness Index, By Source
8.2. Congenital*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Acquired
9. By Treatment
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.1.2. Market Attractiveness Index, By Treatment
9.2. Glucocorticoid*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Corticotropin
9.4. Others
10. By Route of Administration
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Ophthalmology Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Injectables
10.4. Others
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. UK
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Acrotech Biopharma, Inc.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Bausch Health, Canada Inc.
14.3. AdvaCare Pharma
14.4. weefselpharma
14.5. Cipla Inc.
14.6. Pfizer Inc
14.7. Wellona Pharma
14.8. Eugia US
14.9. Sandoz Inc.
14.10. Prevego Healthcare & Research Pvt Ltd.
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Acrotech Biopharma, Inc., 4.	Key Developments, Bausch Health, Canada Inc., AdvaCare Pharma, weefselpharma, Cipla Inc., Pfizer Inc, Wellona Pharma, Eugia US, Sandoz Inc., Prevego Healthcare & Research Pvt Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Adrenal Insufficiency Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Adrenal Insufficiency Market Value, By Source, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Adrenal Insufficiency Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Adrenal Insufficiency Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Adrenal Insufficiency Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Adrenal Insufficiency Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Adrenal Insufficiency Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Adrenal Insufficiency Market Value, By Type, 2021-2030 (US$ Million)

Table 9 Global Adrenal Insufficiency Market Value, By Source, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Adrenal Insufficiency Market Value, By Source, 2021-2030 (US$ Million)

Table 11 Global Adrenal Insufficiency Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Adrenal Insufficiency Market Value, By Treatment, 2021-2030 (US$ Million)

Table 13 Global Adrenal Insufficiency Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 14 Global Adrenal Insufficiency Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 Global Adrenal Insufficiency Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 16 Global Adrenal Insufficiency Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 17 Global Adrenal Insufficiency Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 18 Global Adrenal Insufficiency Market Value, By Region, 2021-2030 (US$ Million)

Table 19 North America Adrenal Insufficiency Market Value, By Type, 2021-2030 (US$ Million)

Table 20 North America Adrenal Insufficiency Market Value, By Source, 2021-2030 (US$ Million)

Table 21 North America Adrenal Insufficiency Market Value, By Treatment, 2021-2030 (US$ Million)

Table 22 North America Adrenal Insufficiency Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 North America Adrenal Insufficiency Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 North America Adrenal Insufficiency Market Value, By Country, 2021-2030 (US$ Million)

Table 25 South America Adrenal Insufficiency Market Value, By Type, 2021-2030 (US$ Million)

Table 26 South America Adrenal Insufficiency Market Value, By Source, 2021-2030 (US$ Million)

Table 27 South America Adrenal Insufficiency Market Value, By Treatment, 2021-2030 (US$ Million)

Table 28 South America Adrenal Insufficiency Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 South America Adrenal Insufficiency Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 South America Adrenal Insufficiency Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Europe Adrenal Insufficiency Market Value, By Type, 2021-2030 (US$ Million)

Table 32 Europe Adrenal Insufficiency Market Value, By Source, 2021-2030 (US$ Million)

Table 33 Europe Adrenal Insufficiency Market Value, By Treatment, 2021-2030 (US$ Million)

Table 34 Europe Adrenal Insufficiency Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 35 Europe Adrenal Insufficiency Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 36 Europe Adrenal Insufficiency Market Value, By Country, 2021-2030 (US$ Million)

Table 37 Asia-Pacific Adrenal Insufficiency Market Value, By Type, 2021-2030 (US$ Million)

Table 38 Asia-Pacific Adrenal Insufficiency Market Value, By Source, 2021-2030 (US$ Million)

Table 39 Asia-Pacific Adrenal Insufficiency Market Value, By Treatment, 2021-2030 (US$ Million)

Table 40 Asia-Pacific Adrenal Insufficiency Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 41 Asia-Pacific Adrenal Insufficiency Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 42 Asia-Pacific Adrenal Insufficiency Market Value, By Country, 2021-2030 (US$ Million)

Table 43 Middle East & Africa Adrenal Insufficiency Market Value, By Type, 2021-2030 (US$ Million)

Table 44 Middle East & Africa Adrenal Insufficiency Market Value, By Source, 2021-2030 (US$ Million)

Table 45 Middle East & Africa Adrenal Insufficiency Market Value, By Treatment, 2021-2030 (US$ Million)

Table 46 Middle East & Africa Adrenal Insufficiency Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 47 Middle East & Africa Adrenal Insufficiency Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 48 Acrotech Biopharma, Inc.: Overview

Table 49 Acrotech Biopharma, Inc.: Product Portfolio

Table 50 Acrotech Biopharma, Inc.: Key Developments

Table 51 Bausch Health, Canada Inc.: Overview

Table 52 Bausch Health, Canada Inc.: Product Portfolio

Table 53 Bausch Health, Canada Inc.: Key Developments

Table 54 AdvaCare Pharma: Overview

Table 55 AdvaCare Pharma: Product Portfolio

Table 56 AdvaCare Pharma: Key Developments

Table 57 weefselpharma: Overview

Table 58 weefselpharma: Product Portfolio

Table 59 weefselpharma: Key Developments

Table 60 Cipla Inc.: Overview

Table 61 Cipla Inc.: Product Portfolio

Table 62 Cipla Inc.: Key Developments

Table 63 Pfizer Inc: Overview

Table 64 Pfizer Inc: Product Portfolio

Table 65 Pfizer Inc: Key Developments

Table 66 Wellona Pharma: Overview

Table 67 Wellona Pharma: Product Portfolio

Table 68 Wellona Pharma: Key Developments

Table 69 Eugia US: Overview

Table 70 Eugia US: Product Portfolio

Table 71 Eugia US: Key Developments

Table 72 Sandoz Inc.: Overview

Table 73 Sandoz Inc.: Product Portfolio

Table 74 Sandoz Inc.: Key Developments

Table 75 Prevego Healthcare & Research Pvt Ltd.: Overview

Table 76 Prevego Healthcare & Research Pvt Ltd.: Product Portfolio

Table 77 Prevego Healthcare & Research Pvt Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 2 Global Adrenal Insufficiency Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Adrenal Insufficiency Market Share, By Source, 2022 & 2030 (%)

Figure 4 Global Adrenal Insufficiency Market Share, By Treatment, 2022 & 2030 (%)

Figure 5 Global Adrenal Insufficiency Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 6 Global Adrenal Insufficiency Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 7 Global Adrenal Insufficiency Market Share, By Region, 2022 & 2030 (%)

Figure 8 Global Adrenal Insufficiency Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 9 Primary Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 10 Secondary Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 11 Tertiary Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 12 Global Adrenal Insufficiency Market Y-o-Y Growth, By Source, 2022-2030 (%)

Figure 13 Congenital Source in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 14 Acquired Source in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 15 Global Adrenal Insufficiency Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 16 Glucocorticoid Treatment in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 17 Corticotropin Treatment in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 18 Others Treatment in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 19 Global Adrenal Insufficiency Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 20 Oral Route of Administration in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 21 Injectables Route of Administration in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 22 Others Route of Administration in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 23 Global Adrenal Insufficiency Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 24 Hospital Pharmacies Distribution Channel in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 25 Retail Pharmacies Distribution Channel in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 26 Online Pharmacies Distribution Channel in Global Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 27 Global Adrenal Insufficiency Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 28 North America Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 29 Asia-Pacific Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 30 Europe Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 31 South America Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 32 Middle East and Africa Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 33 North America Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 34 North America Adrenal Insufficiency Market Share, By Type, 2022 & 2030 (%)

Figure 35 North America Adrenal Insufficiency Market Share, By Source, 2022 & 2030 (%)

Figure 36 North America Adrenal Insufficiency Market Share, By Treatment, 2022 & 2030 (%)

Figure 37 North America Adrenal Insufficiency Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 38 North America Adrenal Insufficiency Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 39 North America Adrenal Insufficiency Market Share, By Country, 2022 & 2030 (%)

Figure 40 South America Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 41 South America Adrenal Insufficiency Market Share, By Type, 2022 & 2030 (%)

Figure 42 South America Adrenal Insufficiency Market Share, By Source, 2022 & 2030 (%)

Figure 43 South America Adrenal Insufficiency Market Share, By Treatment, 2022 & 2030 (%)

Figure 44 South America Adrenal Insufficiency Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 South America Adrenal Insufficiency Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 46 South America Adrenal Insufficiency Market Share, By Country, 2022 & 2030 (%)

Figure 47 Europe Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 48 Europe Adrenal Insufficiency Market Share, By Type, 2022 & 2030 (%)

Figure 49 Europe Adrenal Insufficiency Market Share, By Source, 2022 & 2030 (%)

Figure 50 Europe Adrenal Insufficiency Market Share, By Treatment, 2022 & 2030 (%)

Figure 51 Europe Adrenal Insufficiency Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 52 Europe Adrenal Insufficiency Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 53 Europe Adrenal Insufficiency Market Share, By Country, 2022 & 2030 (%)

Figure 54 Asia-Pacific Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 55 Asia-Pacific Adrenal Insufficiency Market Share, By Type, 2022 & 2030 (%)

Figure 56 Asia-Pacific Adrenal Insufficiency Market Share, By Source, 2022 & 2030 (%)

Figure 57 Asia-Pacific Adrenal Insufficiency Market Share, By Treatment, 2022 & 2030 (%)

Figure 58 Asia-Pacific Adrenal Insufficiency Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 59 Asia-Pacific Adrenal Insufficiency Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 60 Asia-Pacific Adrenal Insufficiency Market Share, By Country, 2022 & 2030 (%)

Figure 61 Middle East & Africa Adrenal Insufficiency Market Value, 2021-2030 (US$ Million)

Figure 62 Middle East & Africa Adrenal Insufficiency Market Share, By Type, 2022 & 2030 (%)

Figure 63 Middle East & Africa Adrenal Insufficiency Market Share, By Source, 2022 & 2030 (%)

Figure 64 Middle East & Africa Adrenal Insufficiency Market Share, By Treatment, 2022 & 2030 (%)

Figure 65 Middle East & Africa Adrenal Insufficiency Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 66 Middle East & Africa Adrenal Insufficiency Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 67 Acrotech Biopharma, Inc.: Financials

Figure 68 Bausch Health, Canada Inc.: Financials

Figure 69 AdvaCare Pharma: Financials

Figure 70 weefselpharma: Financials

Figure 71 Cipla Inc.: Financials

Figure 72 Pfizer Inc: Financials

Figure 73 Wellona Pharma: Financials

Figure 74 Eugia US: Financials

Figure 75 Sandoz Inc.: Financials

Figure 76 Prevego Healthcare & Research Pvt Ltd.: Financials

세계 부신 기능 부전 시장 – 2023-2030

Global Adrenal Insufficiency Market - 2023-2030